Table 4.
Ongoing clinical trials for CAR T cell therapy against AML.
| Target Antigen | Population | NCT ID | Phase |
|---|---|---|---|
| CD33 | R/R AML | NCT03126864 | I |
| R/R AML | NCT02799680 | I | |
| R/R AML | NCT01864902 | I/II | |
| R/R AML | NCT02944162 | I/II | |
| R/R AML, MDS; ALL | NCT03291444 | I | |
| R/R AML | NCT03473457 | ||
| AML | NCT03222674 | I/II | |
| CD123 | AML | NCT03585517 | I |
| Recurred AML after allo-HSCT | NCT03114670 | I | |
| R/R AML | NCT03556982 | I/II | |
| R/R AML | NCT02623582 | I | |
| R/R AML | NCT02159495 | I | |
| R/R AML | NCT03672851 | I | |
| R/R AML | NCT03766126 | I | |
| R/R AML, MDS; ALL | NCT03291444 | I | |
| R/R AML | NCT03473457 | n/a | |
| R/R AML | NCT03796390 | I | |
| AML | NCT03222674 | I/II | |
| CD38 | R/R AML, MDS; ALL | NCT03291444 | I |
| R/R AML | NCT03473457 | ||
| AML | NCT03222674 | I/II | |
| UCART23 | R/R AML | NCT03190278 | I |
| R/R AML, high-risk AML | NCT01864902 | I | |
| CD/123/CLL1 | R/R AML | NCT03631576 | II/III |
| CD33/CLL1 | R/R AML, MDS, MPN, CML | NCT03795779 | I |
| CCL1 | AML | NCT03222674 | I/II |
| NKG2D | AML, MDS-RAEB, MM | NCT02203825 | I |
| R/R AML, AML, Myeloma | NCT03018405 | I/II | |
| Lewis Y | Myeloma, AML, MDS | NCT01716364 | I |
| WT1 | R/R AML, ALL, MDS | NCT03291444 | I |
| CD7/NK92 | R/R AML | NCT03018405 | I/II |